MetaCap

Cerenome (CNSY) vs Intelligent Bio Solutions (INBS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cerenome is the larger company by market cap ($6.2 million vs $4.6 million), about 1.3 times the size, while Intelligent Bio Solutions is growing revenue faster (+38.1% vs -10.5%). Intelligent Bio Solutions converts more of its revenue into profit, with a net margin of -294.9% versus -429.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CNSY-61.46%INBS-12.58%
+49%-11%-71%
Oct 7, 20261 yearNov 20, 2026
CNSY-67.35%INBS-9.15%
+34%-19%-72%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CNSY versus INBS key metrics
MetricCNSYINBS
Share price$0.6301$1.39
Market cap$6.16M$4.61M
1-day change-10.29%-7.95%
YTD return-95.06%—
1-year return-95.24%—
5-year return-99.89%—
Forward P/E—3.97
EPS (TTM)$-3.50$-6.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$5.21M$4.22M
Revenue growth (YoY)-10.49%+38.09%
Net income (latest FY)$-22.39M$-12.43M
Gross margin—48.63%
Operating margin-293.46%-299.11%
Net margin-429.43%-294.91%
52-week high$19.00$24.90
52-week low$0.43$1.35
Distance from 52-week high-96.68%-94.42%
Analyst consensusstrong_buynone
Avg. price target upside+4304.06%+763.31%
Average volume804.18K129.01K
Shares outstanding9.78M3.32M
Employees2859
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Intelligent Bio Solutions is more profitable, keeping -294.9 cents of every revenue dollar as net income versus -429.4 cents for Cerenome.
  • Intelligent Bio Solutions grew revenue faster in its latest fiscal year (+38.09% vs -10.49%).

About Cerenome

CNSY stock →

Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

Health Care · Medical/Dental Instruments · 28 employees

About Intelligent Bio Solutions

INBS stock →

Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform.

Health Care · Medical/Dental Instruments · 59 employees

CNSY vs INBS FAQ

Which is bigger, Cerenome or Intelligent Bio Solutions?

Cerenome (CNSY) is larger, with a market capitalization of $6.16M compared with $4.61M for Intelligent Bio Solutions (INBS).

Are Cerenome and Intelligent Bio Solutions in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons